Crispr/Cas9 is a new method to manipulate the genome.

This technology should be broadly applicable to in vitro studies that require the manipulation of the human genome.

A process for insertional mutagenesis and genome manipulation of yeast, Dictyostelium and mammaliam cells by introducing a recombination substrate is provided.

Manipulation of the human genome also raises ethical questions about how we define which parts of the DNA we decide to alter.

Breakthroughs in recent years in gene editing and manipulation, such as CRISPR,a are opening vast new possibilities in biotechnology.

This favored the proliferation of new strategies for genome manipulation, which can be applied to population control.

Engineered transcriptional activator-like effectors (TALEs) are versatile tools for genome manipulation with applications in research and clinical contexts.

Last year however, events have shown that our societies seem unprepared to confront the Transhumanist hopes that the manipulation of the genome carries in it.

Use of said variant and derived products for genome engineering and for in vivo and ex vivo (gene cell therapy) genome therapy as well as the treatment of a Herpesviridae infection.

Engineered nucleases (e.g., zinc finger nucleases (ZFNs), transcriptional activator-like effector nucleases (TALENs), and others) are promising tools for genome manipulation and determining off-target cleavage sites of these enzymes is of great interest.